Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management;Doit-on doser le marqueur circulant ECD/HER-2 chez les patientes atteintes d'un cancer mammaire ?

Presse Medicale

Volumn 40, Issue 2, 2011, Pages 126-137

  Mathelin, Carole ^a   Croce, Sabrina ^a   Rault, Sébastien ^a   Gharbi, Mouslim ^a   Eichler, Francoise ^a   Gairard, Béatrice ^a   Coumaros, Geneviève ^a   Koehl, Christian ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 EXTRACELLULAR DOMAIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDLINE; METASTASIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 79551564820     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.10.004     Document Type: Article

References (103)

1. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008, 56:159-175.
2. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
3. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230:1132-1139.
4. Schechter A.L., Hung M.C., Vaidyanathan L., Weinberg R.A., Yang-Feng T.L., Francke U., et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985, 229:976-978.
5. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Greene M.I., et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312:513-516.
6. Dybdal N., Leiberman G., Anderson S., McCune B., Bajamonde A., Cohen R.L., et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005, 93:3-11.
7. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
8. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999, 21:309-318.
9. Meijnen P., Peterse J.L., Antonini N., Rutgers E.J., van de Vijver M.J. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008, 98:137-142.
10. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-56.
11. Lower E.E., Glass E., Blau R., Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009, 113:301-306.
12. Gong Y., Booser D.J., Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769.
13. Codony-Servat J., Albanell J., Lopez-Talavera J.C., Arribas J., Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999, 59:1196-1201.
14. Luftner D., Luke C., Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin Biochem 2003, 36:233-240.
15. Sias P.E., Kotts C.E., Vetterlein D., Shepard M., Wong W.L. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 1990, 132:73-80.
16. Muller V., Witzel I., Luck H.J., Kohler G., von Minckwitz G., Mobus V., et al. Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 2004, 86:9-18.
17. Hait W.N. The prognostic and predictive values of ECD-HER-2. Clin Cancer Res 2001, 7:2601-2604.
18. Bramwell V.H., Doig G.S., Tuck A.B., Wilson S.M., Tonkin K.S., Tomiak A., et al. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 2009, 114:503-511.
19. Fehm T., Jager W., Kramer S., Sohn C., Solomayer E., Wallwiener D., et al. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 2004, 24:1987-1992.
20. Thureau S, Clatot F, Pillé J, Laberge-Le-Couteulx S, Rigal O, Veyret C, et al. Prognostic value of serum level of HER-2 extracellular domain (ECD) at diagnosis of HER-2 overexpressed primary breast cancer. ASCO Annual Meeting, J Clin Oncol 2009; 27(suppl);abstr e11508.
21. Abu-Khalaf M.M., Harris L. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer. Breast Cancer Res Treat 2009, 114:513-515.
22. Christianson T.A., Doherty J.K., Lin Y.J., Ramsey E.E., Holmes R., Keenan E.J., et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998, 58:5123-5129.
23. Hayes D.F., Yamauchi H., Broadwater G., Cirrincione C.T., Rodrigue S.P., Berry D.A., et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 2001, 7:2703-2711.
24. Nunes R.A., Harris L.N. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002, 3:125-135. [discussion 136-137].
25. Saghatchian M., Guepratte S., Hacene K., Neumann R., Floiras J.L., Pichon M.F. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 2004, 19.
26. Schippinger W., Regitnig P., Bauernhofer T., Ploner F., Hofmann G., Krippl P., et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep 2004, 11:1331-1336.
27. Fehm T., Maimonis P., Katalinic A., Jager W.H. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998, 55:33-38.
28. Fehm T., Maimonis P., Weitz S., Teramoto Y., Katalinic A., Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997, 43:87-95.
29. Willsher P.C., Beaver J., Pinder S., Bell J.A., Ellis I.O., Blamey R.W., et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996, 40:251-255.
30. Ludovini V., Gori S., Colozza M., Pistola L., Rulli E., Floriani I., et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008, 19:883-890.
31. Quaranta M., Daniele A., Coviello M., Savonarola A., Abbate I., Venneri M.T., et al. c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori 2006, 92:311-317.
32. Molina R., Jo J., Filella X., Zanon G., Pahisa J., Munoz M., et al. c-erbB-2 oncoprotein CEA, and CA 15. 3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998, 51:109-119.
33. Molina R., Filella X., Zanon G., Pahisa J., Alicarte J., Munoz M., et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein CEA and CA 15. 3) in patients with locoregional breast cancer. Anticancer Res 2003, 23:1043-1050.
34. Mehta R.R., McDermott J.H., Hieken T.J., Marler K.C., Patel M.K., Wild L.D., et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998, 16:2409-2416.
35. Moreno-Aspitia A, Hillman D, Dueck A, Carney W, Lingle W, Tenner K, et al. Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): results from the NCCTG adjuvant Intergroup trial N9831. ASCO Annual Meeting, J Clin Oncol 2008 [Abstract] 26:A-529.
36. Ardavanis A., Kountourakis P., Kyriakou F., Malliou S., Mantzaris I., Garoufali A., et al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 2008, 13:361-369.
37. Liu X., Fridman J.S., Wang Q., Caulder E., Yang G., Covington M., et al. Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther 2006, 5:648-656.
38. Gauchez A.S., Colonna M., Brand F.X., Ravanel N., Pasquier D., Payan R., et al. Kinetics of HER2/neu ECD in 45 patients treated with Trastuzumab (Herceptin(R)) between January 2001 and June 2005 at the Grenoble University Hospital. Anticancer Res 2009, 29:1703-1707.
39. Esteva F.J. Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?. Oncologist 2008, 13:370-372.
40. Fornier M.N., Seidman A.D., Schwartz M.K., Ghani F., Thiel R., Norton L., et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005, 16:234-239.
41. Lennon S., Barton C., Banken L., Gianni L., Marty M., Baselga J., et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009, 27:1685-1693.
42. Baselga J., Carbonell X., Castaneda-Soto N.J., Clemens M., Green M., Harvey V., et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-2171.
43. Mazouni C., Hall A., Broglio K., Fritsche H., Andre F., Esteva F.J., et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007, 109:496-501.
44. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer 2005;Res 7:R436-43.
45. Gasparini G., Sarmiento R., Amici S., Longo R., Gattuso D., Zancan M., et al. Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Ann Oncol 2005, 16:1867-1873.
46. Burstein H.J., Harris L.N., Marcom P.K., Lambert-Falls R., Havlin K., Overmoyer B., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003, 21:2889-2895.
47. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:1800-1808.
48. Kostler W.J., Schwab B., Singer C.F., Neumann R., Rucklinger E., Brodowicz T., et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:1618-1624.
49. Kostler W.J., Steger G.G., Soleiman A., Schwab B., Singer C.F., Tomek S., et al. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res 2004, 24:1127-1130.
50. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003, 49:1579-1598.
51. Apostolaki S., Perraki M., Pallis A., Bozionelou V., Agelaki S., Kanellou P., et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007, 18:851-858.
52. Colomer R., Montero S., Lluch A., Ojeda B., Barnadas A., Casado A., et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000, 6:2356-2362.
53. Im S.A., Kim S.B., Lee M.H., Im Y.H., Lee K.H., Song H.S., et al. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor. Oncol Rep 2005, 14:481-487.
54. Schippinger W., Dandachi N., Regitnig P., Hofmann G., Balic M., Neumann R., et al. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer. Am J Clin Pathol 2007, 128:630-637.
55. Harris L.N., Liotcheva V., Broadwater G., Ramirez M.J., Maimonis P., Anderson S., et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001, 19:1698-1706.
56. Revillion F., Hebbar M., Bonneterre J., Peyrat J.P. Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer 1996, 32A:231-234.
57. Colomer R., Llombart-Cussac A., Lloveras B., Ramos M., Mayordomo J.I., Fernandez R., et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. Cancer 2007, 110:2178-2185.
58. Leitzel K., Teramoto Y., Konrad K., Chinchilli V.M., Volas G., Grossberg H., et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995, 13:1129-1135.
59. Lipton A., Leitzel K., Ali S.M., Demers L., Harvey H.A., Chaudri-Ross H.A., et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005, 104:257-263.
60. Lipton A., Ali S.M., Leitzel K., Demers L., Harvey H.A., Chaudri-Ross H.A., et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003, 21:1967-1972.
61. Lipton A., Ali S.M., Leitzel K., Demers L., Chinchilli V., Engle L., et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002, 20:1467-1472.
62. Fehm T., Becker S., Duerr-Stoerzer S., Sotlar K., Mueller V., Wallwiener D., et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007, 9:R74.
63. Salvadori B., Pinzani P., Distante V., Casella D., Bianchi S., Paglierani M., et al. Comparison of pre- and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer. Clin Chem 2005, 51:254-256.
64. Fehm T., Jager W., Kraemer S., Sohn C., Solomayer-Meyberg G., Solomayer E.F., et al. Changes of serum HER2 status during clinical course of metastatic breast cancer patients. Anticancer Res 2004, 24:4205-4210.
65. Asgeirsson K.S., Agrawal A., Allen C., Hitch A., Ellis I.O., Chapman C., et al. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 2007, 9. R75.
66. Kong S.Y., Nam B.H., Lee K.S., Kwon Y., Lee E.S., Seong M.W., et al. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. Clin Chem 2006, 52:1510-1515.
67. Fontana X., Ferrari P., Namer M., Peysson R., Salanon C., Bussiere F. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res 1994, 14:2099-2104.
68. Hoopmann M., Neumann R., Tanasale T., Schondorf T. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study. Anticancer Res 2003, 23:1031-1034.
69. Bethune-Volters A., Labroquere M., Guepratte S., Hacene K., Neumann R., Carney W., et al. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res 2004, 24:1083-1089.
70. Pectasides D., Gaglia A., Arapantoni-Dadioti P., Bobota A., Valavanis C., Kostopoulou V., et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006, 26:647-653.
71. Molina R., Jo J., Filella X., Zanon G., Farrus B., Munoz M., et al. C-erbB-2. CEA and CA 15. 3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999, 19:2551-2555.
72. Sugano K., Kawai T., Ishii M., Koyama H., Kitajima M., Kasumi F., et al. Clinical evaluation of serum ErbB-2 protein using enzyme immuno assay (ErbB-2 EIA [Nichirei]). Gan To Kagaku Ryoho 1994, 21:1255-1262.
73. Kath R., Hoffken K., Otte C., Metz K., Scheulen M.E., Hulskamp F., et al. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol 1993, 4:585-590.
74. Visco V., Bei R., Moriconi E., Gianni W., Kraus M.H., Muraro R. ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. Am J Pathol 2000, 156:1417-1424.
75. McKenzie S.J., Marks P.J., Lam T., Morgan J., Panicali D.L., Trimpe K.L., et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989, 4:543-548.
76. Carney W., Hamer P., Petit D., Retos C., Greene R., Zabrecky J., et al. Detection and quantitation of the neu oncoprotein. J Tumor Marker Oncol 1991, 6:53-72.
77. Cook G.B., Neaman I.E., Goldblatt J.L., Cambetas D.R., Hussain M., Luftner D., et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 2001, 21:1465-1470.
78. Payne R.C., Allard J.W., Anderson-Mauser L., Humphreys J.D., Tenney D.Y., Morris D.L. Automated assay for HER-2/neu in serum. Clin Chem 2000, 46:175-182.
79. Streckfus C., Bigler L., Dellinger T., Dai X., Kingman A., Thigpen J.T. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 2000, 6:2363-2370.
80. Leary A.F., Hanna W.M., van de Vijver M.J., Penault-Llorca F., Ruschoff J., Osamura R.Y., et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009, 27:1694-1705.
81. Narita T., Funahashi H., Satoh Y., Takagi H. C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992, 24:97-102.
82. Isola J.J., Holli K., Oksa H., Teramoto Y., Kallioniemi O.P. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994, 73:652-658.
83. Breuer B., Smith S., Thor A., Edgerton S., Osborne M.P., Minick R., et al. ErbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Res Treat 1998, 49:261-270.
84. Fehm T., Gebauer G., Jager W. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 2002, 75:97-106.
85. Sugano K., Ushiama M., Fukutomi T., Tsuda H., Kitoh T., Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000, 89:329-336.
86. Dittadi R., Zancan M., Perasole A., Gion M. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001, 16:255-261.
87. Imoto S., Wada N., Hasebe T., Ochiai A., Kitoh T. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. Int J Cancer 2007, 120:357-361.
88. Wong W, Bajamonde A, Nelson B, Carney W, Mass R. Baseline serum HER2 (sHER2) levels in the pivotal herceptin breast cancer trials: a comparison of 2 ELISA methods. Proc Am Soc Clin Oncol 2000;19:77a.
89. Pegram M., Lipton A., Hayes D., Weber B., Baselga J., Tripathy D., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998, 1:2659-2671.
90. Leyland-Jones B., Marty M., Baselga J., Gatzemeier U., Barton C., Lennon S.L. Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2004, 22:570.
91. Mielke S., Meden H., Raab T., Wuttke W., Kuhn W. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum. Anticancer Res 1997, 17:3125-3127.
92. Meden H., Mielke S., Marx D., Wuttke W., Kuhn W. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 1997, 17:3075-3077.
93. Molina R., Jo J., Filella X., Bruix J., Castells A., Hague M., et al. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997, 18:188-196.
94. Pichon M.F., Hacene K., Guepratte S., Neumann R. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clin Lab 2004, 50:163-170.
95. Breast Cancers Recommandations for clinical practice from Saint Paul de Vence. Oncologie 2005;7:342-79.
96. Oncologie 2007, 9:593-644. Breast Cancers Recommandations for clinical practice from Saint Paul de Vence.
97. Brodowicz T., Wiltschke C., Budinsky A.C., Krainer M., Steger G.G., Zielinski C.C. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 1997, 73:875-879.
98. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99:628-638.
99. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
100. Ali S.M., Esteva F.J., Fornier M., Gligorov J., Harris L., Kostler W.J., et al. Serum HER-2/neu change predicts clinical outcome to trastuzumab based therapy. J Clin Oncol ASCO Meeting Abstracts 2006, 24:500.
101. Colomer R., Llombart-Cussac A., Lluch A., Barnadas A., Ojeda B., Caranana V., et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 2004, 15:201-206.
102. Colomer R., Llombart-Cussac A., Tusquets I., Rifa J., Mayordomo J.I., Ojeda B., et al. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain. Clin Transl Oncol 2006, 8:896-902.
103. Yamauchi H., O'Neill A., Gelman R., Carney W., Tenney D.Y., Hosch S., et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997, 15:2518-2525.